Egle Therapeutics

Egle Therapeutics is a biotech company developing immunotherapies for oncology and autoimmune diseases. It uses its target discovery technology platform to build a drug pipeline of immunotherapies against Tregs (T cells). The company removes tumor-infiltrating Tregs through a series of IL-2 (Interleukin-2) variants enabling healthcare professionals to develop therapies targeting immune suppressor regulatory for treating cancer and other diseases.